Digest

Abstract Prescribing prospects promising US pharmaceutical companies have no fewer than 119 new drugs in development for the treatment of mental health disorders and addiction, according to a report from the Pharmaceutical Research and Manufacturers of America (www.phrma.org). There are 36 pipeline products for schizophrenia, including selective phosphodiesterase inhibitors, which may be effective against negative symptoms and do not cause cognitive impairment. The 44 new drugs for depression or anxiety disorders include a combined opioid modulator/agonist and a new class of pherines for social anxiety disorder. A triple noradrenaline/dopamine/serotonin reuptake inhibitor is among 15 products in development for ADHD and a therapeutic vaccine for cocaine addiction is one of 20 drugs being developed for addiction disorders.
Source: Progress in Neurology and Psychiatry - Category: Neurology Tags: Digest Source Type: research